Expert Interview
A Second Look: Discussing the recent FDA approval of Amgen's LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Ticker(s): AMGNInstitution: Duke University
- Gastrointestinal Oncologist and Professor of Medicine in the Department of Surgery at Duke University
- Manages 50+ patients a year with colorectal cancer
- Research interest in immune therapies for treating GI cancers
Can you discuss your professional background, clinical practice, and the prevalence of KRAS G12C mutations in your mCRC patients?
How has the approval of Lumakras + Vectibix changed the treatment landscape compared to previous standards and the approval of Adagrasib + Cetuximab?
How do the efficacy and safety profiles of Lumakras + Vectibix compare to Krazati-based regimens, and what role does toxicity play in treatment choice?
What barriers exist to accessing Lumakras, and how do they compare to challenges with Krazati? What percentage of second-line patients could realistically receive Lumakras + Vectibix given these constraints?
Added By: sara_adminWhat are your thoughts on Amgen’s CodeBreaK 301 trial using Lumakras + Panitumumab + Folfiri, and why was Folfiri chosen over Folfox? Should future trials explore non-G12C KRAS mutations?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
